Merck, Pfizer tout PhIII diabetes data as ertuglifozin heads to the FDA
Merck and Pfizer rolled out positive Phase III data for their SGLT2 diabetes drug ertugliflozin at the annual EASD meeting in Germany today.
The data, with two doses of their drug added to Januvia and metformin slicing A1c levels by an extra 0.69 percent and 0.76 percent, will be added to their regulatory filings for this drug, now slated to land at the FDA before the end of this year with Europe and other markets to follow in 2017.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.